Genkyotex Plans 'Solo' Pivotal Trials After Lead Product Hits Phase II PBC Targets

 
• By Sten Stovall

The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.

Cirrhosis
Primary biliary cholangitis causes the immune system to attack bile ducts • Source: Shutterstock

More from Business

More from Scrip